As of September 19, 2023, the German federal government has revealed its plans to distribute approximately 10.6 million doses of the Novavax COVID-19 vaccine to its citizens in the fourth quarter of the same year, pending approval. Unlike mRNA vaccines, this particular vaccine is a protein-based preparation. Currently, the Novavax COVID-19 Vaccine, Adjuvanted, is accessible under emergency use authorization (EUA) in the United States for individuals aged 12 and above, serving as a preventive measure against COVID-19. It has been authorized for emergency use to administer a two-dose primary series to individuals aged 12 and above, as well as a first booster dose to specific individuals who have already completed their primary vaccination with an authorized or approved COVID-19 vaccine, with at least 6 months having passed.
Updated on: 19/09/2023
Debt to equity ratio: Strong Sell
Price to earnings ratio: Sell
Price to book ratio: Sell
DCF: Strong Buy
8:00 PM (UTC)
Date:19 September, 2023
|Analyst / firm||Rating|
NVAX Stock Analysis: Stable Day in the Market with Impressive Earnings Growth, but Projected Decline Ahead
On September 19, 2023, Novavax Inc. (NVAX) experienced a relatively stable day in the stock market. The stock opened at $7.42, just one cent higher than the previous closing price of $7.41. Throughout the day, the stock’s price fluctuated within a range of $7.38 to $7.71. The total volume of shares traded was 186,929, which is significantly lower than the average volume of 7,837,815 shares over the past three months.
Despite the lower trading volume, NVAX’s market capitalization remains at $747.2 million. The company has shown impressive earnings growth over the past year, with a growth rate of 64.09%. Furthermore, the earnings growth for this year is even higher at 74.87%. However, analysts predict a decline in earnings growth over the next five years, with a projected growth rate of -69.66%.
NVAX has also demonstrated strong revenue growth over the past year, with an increase of 72.89%. However, the company’s financials reveal that it has not been profitable, with a net loss of $657.9 million in the last year. The net profit margin stands at -33.20%, indicating that the company is operating at a loss.
In terms of valuation, NVAX’s price/sales ratio is 0.41, suggesting that the stock is relatively undervalued compared to its annual revenue. However, the price/book ratio is not available, making it difficult to assess the company’s book value.
NVAX operates in the health technology sector, specifically in the biotechnology industry. The company is headquartered in Gaithersburg, Maryland.
In comparison to other biotechnology stocks, NVAX’s performance on September 19, 2023, was relatively stable. Editas Medicine Inc. had no change in stock price, while Regenxbio Inc. and Rapt Therapeutics Inc. experienced slight declines of -0.84% and -1.83%, respectively.
Investors should keep an eye on NVAX’s next reporting date, which is scheduled for November 2, 2023. Analysts forecast an earnings per share (EPS) of -$0.39 for this quarter. Additionally, the company’s annual revenue for the previous year was $2.0 billion, indicating a significant market presence.
Overall, while NVAX has shown strong earnings and revenue growth, it is important to consider the company’s current financial losses and the projected decline in earnings growth over the next five years. Investors should carefully evaluate the risks and potential rewards before making any investment decisions regarding NVAX stock.
NVAX Stock Shows Strong Performance and Promising Investment Opportunity in September 2023
NVAX stock has been performing well on September 19, 2023, based on the information provided by CNN Money. The 5 analysts offering 12-month price forecasts for Novavax Inc have a median target of $15.00. The median estimate of $15.00 represents a significant increase of 101.61% from the last price of $7.44. Furthermore, the current consensus among 6 polled investment analysts is to buy stock in Novavax Inc. In terms of financial performance, Novavax Inc reported earnings per share of -$0.39 for the current quarter. Additionally, Novavax Inc reported sales of $344.2 million for the current quarter. Investors should keep an eye on Novavax Inc as it approaches its reporting date on November 02. Overall, based on the analysts’ forecasts and the consensus buy rating, NVAX stock appears to be a promising investment opportunity. However, as with any investment, it is important for investors to conduct their own research and consider their risk tolerance before making any decisions.